๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease

โœ Scribed by Nicola Greenberg; Antonio Grassano; Madhav Thambisetty; Simon Lovestone; Cristina Legido-Quigley

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
149 KB
Volume
30
Category
Article
ISSN
0173-0835

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Glucose metabolic rate and progression o
Glucose metabolic rate and progression of illness in Alzheimer's disease
โœ Benjamin V. Siegel Jr.; Monte S. Buchsbaum; Arnold Starr; Richard C. Mohs; Dirce ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 742 KB

## Abstract Thirtyโ€eight patients with mild to moderate Alzheimer's disease (AD) underwent a neuropsychological test battery and 18โ€fluoroโ€2โ€deoxyglucose (FDG) positron emission tomography (PET) before beginning and at the end of a randomized doubleโ€blind study of an experimental treatment. Twelve

Measurement of progression in Alzheimer'
Measurement of progression in Alzheimer's disease: a clinician's perspective
โœ Douglas J. Gelb ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 2 views

Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or

Elevated glutathione as a therapeutic st
Elevated glutathione as a therapeutic strategy in Alzheimer's disease
โœ D. Allan Butterfield; Chava B. Pocernich; Jennifer Drake ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 105 KB ๐Ÿ‘ 2 views

## Abstract Alzheimer's disease (AD) is characterized by progressive loss of memory and cognition. Our laboratory and many others have shown that the AD brain is under extensive oxidative stress. Numerous therapeutic approaches to AD therapy have been hypothesized. Among these are exogenous antioxi

Memory rehabilitation in Alzheimer's dis
Memory rehabilitation in Alzheimer's disease: a review of progress
โœ Luc P. De Vreese; Mirco Neri; Mario Fioravanti; Luciano Belloi; Orazio Zanetti ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 158 KB

## Background: Memory rehabilitation is a sadly misrepresented area of applied research in alzheimer's disease. ## Objectives: To gather and evaluate recent evidence for the clinical effectiveness or ecologically validity of memory rehabilitation for mild to moderate alzheimer's patients. ## Met

Initiating and monitoring cholinesterase
Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease
โœ Gregory R. J. Swanwick; Brian A. Lawlor ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 75 KB ๐Ÿ‘ 2 views

The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a number of clinical and ethical questions. Many of the guidelines published in an attempt to tackle these questions lack either clinical or scientiยฎc validity. Against this background a model is prop